Up and Down γ-Synuclein Transcription in Dopamine Neurons Translates into Changes in Dopamine Neurotransmission and Behavioral Performance in Mice.
AAV vector
antisense oligonucleotide
cognitive dysfunction
dopamine
motor deficits
γ-synuclein
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
04 Feb 2022
04 Feb 2022
Historique:
received:
10
01
2022
revised:
31
01
2022
accepted:
02
02
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
9
4
2022
Statut:
epublish
Résumé
The synuclein family consists of α-, β-, and γ-Synuclein (α-Syn, β-Syn, and γ-Syn) expressed in the neurons and concentrated in synaptic terminals. While α-Syn is at the center of interest due to its implication in the pathogenesis of Parkinson's disease (PD) and other synucleinopathies, limited information exists on the other members. The current study aimed at investigating the biological role of γ-Syn controlling the midbrain dopamine (DA) function. We generated two different mouse models with: (i) γ-Syn overexpression induced by an adeno-associated viral vector and (ii) γ-Syn knockdown induced by a ligand-conjugated antisense oligonucleotide, in order to modify the endogenous γ-Syn transcription levels in midbrain DA neurons. The progressive overexpression of γ-Syn decreased DA neurotransmission in the nigrostriatal and mesocortical pathways. In parallel, mice evoked motor deficits in the rotarod and impaired cognitive performance as assessed by novel object recognition, passive avoidance, and Morris water maze tests. Conversely, acute γ-Syn knockdown selectively in DA neurons facilitated forebrain DA neurotransmission. Importantly, modifications in γ-Syn expression did not induce the loss of DA neurons or changes in α-Syn expression. Collectively, our data strongly suggest that DA release/re-uptake processes in the nigrostriatal and mesocortical pathways are partially dependent on substantia nigra pars compacta /ventral tegmental area (SNc/VTA) γ-Syn transcription levels, and are linked to modulation of DA transporter function, similar to α-Syn.
Identifiants
pubmed: 35163729
pii: ijms23031807
doi: 10.3390/ijms23031807
pmc: PMC8836558
pii:
doi:
Substances chimiques
alpha-Synuclein
0
gamma-Synuclein
0
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : CIBERSAM
ID : CB/07/09/0034
Organisme : Ministry of Science and Innovation (MICINN) and European Regional Development Fund (ERDF), EU
ID : SAF2016-75797-R, PID2019-105136RB-100
Références
Acta Neuropathol Commun. 2014 Sep 11;2:132
pubmed: 25209836
Neuron. 2010 Jan 14;65(1):66-79
pubmed: 20152114
J Neurosci. 1997 Jul 15;17(14):5255-62
pubmed: 9204909
FASEB J. 2003 Nov;17(14):2151-3
pubmed: 12958153
Genome Biol. 2002;3(1):REVIEWS3002
pubmed: 11806835
Mol Ther Methods Clin Dev. 2019 Jul 03;14:180-188
pubmed: 31380464
Clin Chem Lab Med. 2001 Apr;39(4):308-12
pubmed: 11388653
Neuroscience. 2019 Jul 1;410:41-54
pubmed: 31078687
J Comp Neurol. 2005 Mar 14;483(3):351-73
pubmed: 15682395
Science. 1997 Jun 27;276(5321):2045-7
pubmed: 9197268
Exp Cell Res. 2011 Jun 10;317(10):1330-9
pubmed: 20974125
Neuropharmacology. 2008 Jul;55(1):63-70
pubmed: 18538356
Methods Mol Biol. 2011;807:93-118
pubmed: 22034027
Eur J Neurosci. 2008 Jun;27(11):2938-51
pubmed: 18588534
Neuroscience. 2009 Mar 17;159(2):501-13
pubmed: 19361478
Int Rev Cell Mol Biol. 2008;270:225-317
pubmed: 19081538
J Biol Chem. 2003 Apr 25;278(17):15313-8
pubmed: 12586824
Int J Mol Sci. 2021 Mar 13;22(6):
pubmed: 33805843
Pharmacol Ther. 2021 Nov;227:107873
pubmed: 33915178
J Neurosci Res. 2010 Jun;88(8):1764-76
pubmed: 20029978
Science. 2003 Oct 31;302(5646):841
pubmed: 14593171
Eur J Pharmacol. 1977 Jan 21;41(2):133-43
pubmed: 832672
Cancer Res. 1997 Feb 15;57(4):759-64
pubmed: 9044857
Biochemistry. 2005 Oct 18;44(41):13612-24
pubmed: 16216085
Neurosci Lett. 2003 Apr 17;340(3):189-92
pubmed: 12672538
Neuroscience. 2016 Dec 17;339:644-654
pubmed: 27789382
Neuropharmacology. 2012 Sep;63(4):675-84
pubmed: 22652058
Mol Ther Methods Clin Dev. 2020 Apr 11;17:771-784
pubmed: 32355866
Mol Ther. 2018 Feb 7;26(2):550-567
pubmed: 29273501
Commun Integr Biol. 2013 Nov 1;6(6):e26794
pubmed: 24563712
Neuroscience. 2008 Apr 9;152(4):1024-31
pubmed: 18355970
Ann Neurol. 2004 Oct;56(4):591-5
pubmed: 15455394
FEBS Lett. 2011 Apr 6;585(7):1001-6
pubmed: 21396366
EBioMedicine. 2020 Sep;59:102944
pubmed: 32810825
Cereb Cortex. 2017 Jun 1;27(6):3125-3139
pubmed: 27252352
Dement Geriatr Cogn Disord. 2008;26(1):32-42
pubmed: 18577885
J Neurosci. 2006 Nov 15;26(46):11915-22
pubmed: 17108165
J Neurosci. 2011 May 18;31(20):7264-74
pubmed: 21593311
Trends Cell Biol. 2017 Jul;27(7):468-479
pubmed: 28259601
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469-73
pubmed: 9600990
Proc Natl Acad Sci U S A. 1984 Feb;81(3):659-63
pubmed: 6322160
Nat Rev Neurosci. 2001 Jan;2(1):51-61
pubmed: 11253359
J Neurochem. 2006 Jan;96(2):473-81
pubmed: 16336224
J Comp Neurol. 2003 Nov 24;466(4):478-94
pubmed: 14566944
Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13450-5
pubmed: 10557341
Front Neuroanat. 2019 Nov 26;13:93
pubmed: 31849618
Mol Psychiatry. 2016 Mar;21(3):328-38
pubmed: 26100539
Mol Neurobiol. 2004 Jun;29(3):243-59
pubmed: 15181237
J Parkinsons Dis. 2017;7(s1):S51-S69
pubmed: 28282814
Neuron. 2000 Jan;25(1):239-52
pubmed: 10707987
Brain Res. 1995 Jun 5;682(1-2):215-21
pubmed: 7552315
EMBO J. 2004 Nov 10;23(22):4506-16
pubmed: 15510220
BMC Neurosci. 2013 May 14;14:53
pubmed: 23672583
Eur J Neurosci. 2008 Feb;27(4):947-57
pubmed: 18333965
Int J Mol Sci. 2021 Jun 15;22(12):
pubmed: 34203739
J Comp Neurol. 2006 Oct 10;498(5):581-92
pubmed: 16917821
Brain Res. 2011 Mar 25;1382:37-44
pubmed: 21276428
Hum Gene Ther. 2007 Mar;18(3):195-206
pubmed: 17343566
J Neurosci. 2002 Oct 15;22(20):8797-807
pubmed: 12388586
Eur J Neurosci. 2004 Dec;20(11):3085-91
pubmed: 15579163
Eur J Neurosci. 2007 Jan;25(1):106-18
pubmed: 17241272
Science. 2010 Sep 24;329(5999):1663-7
pubmed: 20798282
Int J Neuropsychopharmacol. 2011 Feb;14(1):53-68
pubmed: 20701825
Proc Natl Acad Sci U S A. 2004 Oct 12;101(41):14966-71
pubmed: 15465911
Mol Cell Proteomics. 2016 Oct;15(10):3126-3138
pubmed: 27507836
J Neurosci. 2004 Jun 30;24(26):5901-8
pubmed: 15229237
Synapse. 2000 Nov;38(2):114-23
pubmed: 11018785
J Neurosci. 2004 Dec 8;24(49):11165-70
pubmed: 15590933
Neuroscience. 1990;37(1):11-21
pubmed: 2243588
Neurobiol Dis. 2007 Oct;28(1):83-9
pubmed: 17689254
J Neurosci. 1985 Jun;5(6):1513-21
pubmed: 4009243
Front Mol Neurosci. 2015 Jul 28;8:36
pubmed: 26283910
Neuroscience. 2002;113(2):463-78
pubmed: 12127102
CNS Neurol Disord Drug Targets. 2018;17(8):604-607
pubmed: 30047337
Mol Psychiatry. 2001 Nov;6(6):657-64
pubmed: 11673793
J Neurosci. 1998 Apr 1;18(7):2697-708
pubmed: 9502827